Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer.
Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, Kawabata H, Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T. Ozaki Y, et al. Among authors: kitano s. Data Brief. 2022 Sep 1;45:108558. doi: 10.1016/j.dib.2022.108558. eCollection 2022 Dec. Data Brief. 2022. PMID: 36118297 Free PMC article.
CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy.
Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, Fukui K, Shiono A, Mouri A, Nishihara F, Miura Y, Hashimoto K, Murayama Y, Kaira K, Kobayashi K. Kagamu H, et al. Among authors: kitano s. Cancer Immunol Res. 2020 Mar;8(3):334-344. doi: 10.1158/2326-6066.CIR-19-0574. Epub 2019 Dec 23. Cancer Immunol Res. 2020. PMID: 31871122
Phase I study of tamibarotene monotherapy in pediatric and young adult patients with recurrent/refractory solid tumors.
Nitani C, Hara J, Kawamoto H, Taguchi T, Kimura T, Yoshimura K, Hamada A, Kitano S, Hattori N, Ushijima T, Ono H, Nakamoto M, Higuchi T, Sato A. Nitani C, et al. Among authors: kitano s. Cancer Chemother Pharmacol. 2021 Jul;88(1):99-107. doi: 10.1007/s00280-021-04271-9. Epub 2021 Apr 7. Cancer Chemother Pharmacol. 2021. PMID: 33829292 Clinical Trial.
Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR.
Ueno T, Kitano S, Masuda N, Ikarashi D, Yamashita M, Chiba T, Kadoya T, Bando H, Yamanaka T, Ohtani S, Nagai S, Nakayama T, Takahashi M, Saji S, Aogi K, Velaga R, Kawaguchi K, Morita S, Haga H, Ohno S, Toi M. Ueno T, et al. Among authors: kitano s. BMC Med. 2022 Apr 25;20(1):136. doi: 10.1186/s12916-022-02332-1. BMC Med. 2022. PMID: 35462552 Free PMC article.
Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B).
Ozaki Y, Tsurutani J, Mukohara T, Iwasa T, Takahashi M, Tanabe Y, Kawabata H, Masuda N, Futamura M, Minami H, Matsumoto K, Yoshimura K, Kitano S, Takano T. Ozaki Y, et al. Among authors: kitano s. Eur J Cancer. 2022 Aug;171:193-202. doi: 10.1016/j.ejca.2022.05.014. Epub 2022 Jun 18. Eur J Cancer. 2022. PMID: 35728379 Free article. Clinical Trial.
Different characteristics of the tumor immune microenvironment among subtypes of salivary gland cancer.
Nagatani Y, Kiyota N, Imamura Y, Koyama T, Funakoshi Y, Komatsu M, Itoh T, Teshima M, Nibu KI, Sakai K, Nishio K, Shimomura M, Nakatsura T, Ikarashi D, Nakayama T, Kitano S, Minami H. Nagatani Y, et al. Among authors: kitano s. Asia Pac J Clin Oncol. 2024 Dec;20(6):779-788. doi: 10.1111/ajco.14108. Epub 2024 Sep 4. Asia Pac J Clin Oncol. 2024. PMID: 39233454
Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Fujiwara Y, Tamura K, Kondo S, Tanabe Y, Iwasa S, Shimomura A, Kitano S, Ogasawara K, Turner PK, Mori J, Asou H, Chan EM, Yamamoto N. Fujiwara Y, et al. Among authors: kitano s. Cancer Chemother Pharmacol. 2016 Aug;78(2):281-8. doi: 10.1007/s00280-016-3085-8. Epub 2016 Jun 16. Cancer Chemother Pharmacol. 2016. PMID: 27312735 Clinical Trial.
1,214 results